Nautilus Biotechnology (NAUT) Operating Leases (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Operating Leases data on file, last reported at $28.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 1.6% year-over-year to $28.9 million; the trailing twelve-month figure through Mar 2026 stood at $28.9 million (down 1.6% YoY), and the FY2025 full-year result was $26.2 million, down 0.74% from the prior year.
• Operating Leases grew to $28.9 million in Q1 2026, from $26.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $37.3 million in Q1 2023 to a low of $26.2 million in Q4 2025.
• A 5-year average of $30.1 million and a median of $29.3 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 786.27% in 2022 and dropped 15.15% in 2024, its largest moves.
• Tracing NAUT's Operating Leases over 5 years: stood at $28.3 million in 2022, then rose by 9.72% to $31.1 million in 2023, then retreated by 15.15% to $26.4 million in 2024, then decreased by 0.74% to $26.2 million in 2025, then gained by 10.26% to $28.9 million in 2026.
• Business Quant data shows NAUT's Operating Leases at $28.9 million in Q1 2026, $26.2 million in Q4 2025, and $27.0 million in Q3 2025.